![](jpg/gettyimages-1134798557-150x150.jpg)
Software
-
Artificial Intelligence, BioPharma, Health Tech
FDA Forms New Digital Health Advisory Committee to Cover Growing Role of Tech
The FDA’s digital health advisory committee will discuss technologies such as artificial intelligence and machine learning, virtual reality, and digital therapeutics as well as topics like decentralized clinical trials and patient-generated health data. Committee member nominations are due in December.
-
Pharma, Artificial Intelligence, BioPharma
Sanofi Adds Biologics to Its AI Ambitions, Striking Up R&D Alliance With BioMap
Formed by Baidu founder and CEO Robin Li, BioMap uses artificial intelligence technology to glean insight into proteins to guide biologic drug discovery. The startup is the latest company to join a growing list of Sanofi partners as the pharmaceutical giant continues investing in AI-enabled drug discovery.
-
Jorie Healthcare CEO Shares Why Automation is Critical to Revenue Cycle Management
The revenue cycle management business is using AI tools to automate cumbersome tasks to help hospitals operate more efficiently. It’s beginning to attract the attention of major healthcare organizations.
-
Artificial Intelligence, BioPharma
Already Partnered With Nvidia, Iambic Adds $100M for AI Drug Discovery
Iambic Therapeutics brings together software engineers and drug-hunting scientists, all sharing the goal of using artificial intelligence to optimize properties of small molecule drugs. The startup will apply its Series B financing to a cancer drug pipeline that includes two candidates on track for the clinic in 2024.
-
Devices & Diagnostics, BioPharma
FDA Authorizes Better Therapeutics Mobile App for Treating Type 2 Diabetes
Better Therapeutics prescription digital therapeutic, AspyreRx, received De Novo FDA authorization for type 2 diabetes. The mobile app digitizes and personalizes cognitive behavioral therapy.
-
Health Tech Startups Show Stakeholders How Digital Solutions Can Offer ROI
A panel during the MedCity News INVEST conference discussed what digital health technologies need to do to demonstrate return on investment for payers, providers, and other stakeholders.
-
Devices & Diagnostics, Artificial Intelligence, BioPharma
INVEST Pitch Perfect winner: BeCare Link brings MS assessments to patients’ homes
BeCare Link has developed software that enables the traditional in-person multiple sclerosis assessment to be done remotely on a patient’s own mobile device. The startup was named the winner of MedCity’s recent Pitch Perfect contest.
-
Devices & Diagnostics, BioPharma
Pear Therapeutics pares down its plans as restructuring cuts 9% of workforce
Pear Therapeutics is implementing a corporate restructuring projected to save about $28 million. The goal is to extend its available cash as the company presses on with commercialization efforts for its digital therapeutics.
-
Devices & Diagnostics, Artificial Intelligence, BioPharma
INVEST Pitch Perfect winner: Modality.ai makes Tina the Alexa of clinical trials
Modality.ai has developed a conversational AI system that replaces in-person interviews that are part of neurological assessments for a range of disorders. The startup was judged co-winner in the pharmatech category during the recent MedCity INVEST conference in Chicago.
-
BioPharma, Health Tech, Patient Engagement
INVEST Pitch Perfect winner: Athelo helps patients navigate cancer journey
Athelo Health’s software is a personal coach that supports women with breast and gynecological cancers. The startup was judged co-winner in the pharmatech category during the recent MedCity INVEST conference in Chicago.
-
Navigating Healthcare’s Data Revolution: Priorities, Opportunities, and Challenges for Health Systems
Arcadia recently partnered with HIMSS Market Insights to survey executives, IT, technology, and clinical leaders. Here’s what we found.
-
Pharma, Artificial Intelligence, BioPharma
AI startup Unlearn adds $50M for better, faster, smaller & cheaper clinical trials
Unlearn.AI’s Series B round follows a positive European Medicines Agency draft opinion finding that the company’s artificial intelligence technology can be used in Phase 2 and Phase 3 clinical trials. The startup is now on the hunt for pharmaceutical partners that want to use this “digital twin” technology to speed up their clinical research.
-
Devices & Diagnostics, Artificial Intelligence, BioPharma
Diabetes data put Better Therapeutics’ digital offering on track for FDA filing
Better Therapeutics reported that its digital therapeutic for type 2 diabetes met the main goal of a pivotal study. An FDA submission is expected in the middle of this year, followed by additional clinical trials testing digital therapeutics developed for other cardiometabolic disorders.
-
RNA biotech Nutcracker Therapeutics unshells $167M for drugs built on biochips
ARCH Venture Partners led the Series C round of financing for Nutcracker Therapeutics, a company developing new RNA drugs. The company’s process for developing and manufacturing RNA therapies borrows from techniques used in the technology sector.
-
Pharma, Artificial Intelligence, BioPharma
Harvard spinout Nabla Bio lands $11M to bring AI technology to antibody design
Nabla Bio emerged from the lab of famed Harvard scientist George Church last year, and its antibody discovery technology has already led to five partnerships with pharma and biotech companies. The startup just closed an $11 million seed financing that will support further development of its technology.
-
With $100M ReCept M&A deal, Omnicell enters growing specialty pharmacy space
Specialty drugs represent a growing share of overall pharmaceutical sales, and Omnicell is acquiring specialty pharmacy technologies company ReCept Pharmacy to enter this market. Omnicell is paying $100 million cash to buy ReCept.